These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 23436565)

  • 41. ELISA system for detection of immune responses to FVIII: a study of 246 samples and correlation with the Bethesda assay.
    Sahud MA; Pratt KP; Zhukov O; Qu K; Thompson AR
    Haemophilia; 2007 May; 13(3):317-22. PubMed ID: 17498082
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Plasmatic tissue factor pathway inhibitor is a major determinant of clotting in factor VIII inhibited plasma or blood.
    Knappe S; Gorczyca ME; Jilma B; Derhaschnig U; Hartmann R; Palige M; Scheiflinger F; Dockal M
    Thromb Haemost; 2013 Mar; 109(3):450-7. PubMed ID: 23348798
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical utility of sample preheat treatment in a modified Nijmegen-Bethesda assay (mNBA) for inhibitor monitoring in congenital and acquired haemophilia A: A single-centre four-year experience.
    Gandhi T; Lawler P; Foxton E; Chowdary P; Riddell A
    Haemophilia; 2020 Nov; 26(6):e300-e307. PubMed ID: 32892451
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative measurement of anti-factor VIII antibody by Bethesda assay and ELISA reveals restricted isotype profile and epitope specificity.
    Towfighi F; Gharagozlou S; Sharifian RA; Kazemnejad A; Esmailzadeh K; Managhchi MR; Shokri F
    Acta Haematol; 2005; 114(2):84-90. PubMed ID: 16103630
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Factor VIII activity of BAY 94-9027 is accurately measured with most commonly used assays: Results from an international laboratory study.
    Church N; Leong L; Katterle Y; Ulbrich HF; Noerenberg I; Kitchen S; Michaels LA
    Haemophilia; 2018 Sep; 24(5):823-832. PubMed ID: 29984531
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A chromogenic substrate method for detecting and titrating anti-factor VIII antibodies in the presence of lupus anticoagulant.
    Blanco AN; Alcira Peirano A; Grosso SH; Gennari LC; Pérez Bianco R; Lazzari MA
    Haematologica; 2002 Mar; 87(3):271-8. PubMed ID: 11869939
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Factor VIII-hydrolyzing IgG in acquired and congenital hemophilia.
    Wootla B; Mahendra A; Dimitrov JD; Friboulet A; Borel-Derlon A; Rao DN; Uda T; Borg JY; Bayry J; Kaveri SV; Lacroix-Desmazes S
    FEBS Lett; 2009 Aug; 583(15):2565-72. PubMed ID: 19595998
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Laboratory performance in the World Federation of Hemophilia EQA programme, 2003-2008.
    Jennings I; Kitchen DP; Woods TA; Kitchen S; Walker ID; Preston FE
    Haemophilia; 2009 Mar; 15(2):571-7. PubMed ID: 19175423
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neutralizing antiidiotypic antibodies to factor VIII inhibitors after desensitization in patients with hemophilia A.
    Gilles JG; Desqueper B; Lenk H; Vermylen J; Saint-Remy JM
    J Clin Invest; 1996 Mar; 97(6):1382-8. PubMed ID: 8617869
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Factor VIII Activity and Inhibitor Assays in the Diagnosis and Treatment of Hemophilia A.
    Castellone DD; Adcock DM
    Semin Thromb Hemost; 2017 Apr; 43(3):320-330. PubMed ID: 27272962
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Laboratory testing for von Willebrand's disease: an assessment of current diagnostic practice and efficacy by means of a multi-laboratory survey. RCPA Quality Assurance Program (QAP) in Haematology Haemostasis Scientific Advisory Panel.
    Favaloro EJ; Smith J; Petinos P; Hertzberg M; Koutts J
    Thromb Haemost; 1999 Oct; 82(4):1276-82. PubMed ID: 10544913
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Haemophilia A and von Willebrand's disease.
    Goodeve AC; Rosén S; Verbruggen B
    Haemophilia; 2010 Jul; 16 Suppl 5():79-84. PubMed ID: 20590861
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Novel assays in the coagulation laboratory: a clinical and laboratory perspective.
    Teichman J; Chaudhry HR; Sholzberg M
    Transfus Apher Sci; 2018 Aug; 57(4):480-484. PubMed ID: 30093248
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Performance of recalibrated ReFacto laboratory standard in the measurement of FVIII plasma concentration via the chromogenic and one-stage assays after infusion of recalibrated ReFacto (B-domain deleted recombinant factor VIII).
    Santoro C; Iorio A; Ferrante F; Pallotta A; Pignoloni P; Biondo F; Agnelli G; Mazzucconi MG
    Haemophilia; 2009 May; 15(3):779-87. PubMed ID: 19298379
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Kinetic parameters of monoclonal antibodies ESH2, ESH4, ESH5, and ESH8 on coagulation factor VIII and their influence on factor VIII activity.
    Egler C; Albert T; Brokemper O; Zabe-Kühn M; Mayer G; Oldenburg J; Schwaab R
    J Mol Recognit; 2009; 22(4):301-6. PubMed ID: 19266540
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of low-dose rituximab in a refractory acquired factor VIII inhibitor case secondary to pemphigus.
    Gao Y; Liu S; Ma G; Lv L; Su Y
    Acta Haematol; 2012; 127(1):20-2. PubMed ID: 21996575
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An ELISA system to detect anti-factor VIII antibodies without interference by lupus anticoagulants. Preliminary data in hemophilia A patients.
    Blanco AN; Peirano AA; Grosso SH; Gennari LC; Bianco RP; Lazzari MA
    Haematologica; 2000 Oct; 85(10):1045-50. PubMed ID: 11025595
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Multilaboratory testing of thrombophilia: current and past practice in Australasia as assessed through the Royal College of Pathologists of Australasia Quality Assurance Program for Hematology.
    Favaloro EJ; Bonar R; Sioufi J; Wheeler M; Low J; Aboud M; Duncan E; Smith J; Exner T; Lloyd J; Marsden K;
    Semin Thromb Hemost; 2005 Feb; 31(1):49-58. PubMed ID: 15706475
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Anti-factor VIII inhibitors and lupus anticoagulants in haemophilia A patients.
    Blanco AN; Cardozo MA; Candela M; Santarelli MT; Pérez Bianco R; Lazzari MA
    Thromb Haemost; 1997 Apr; 77(4):656-9. PubMed ID: 9134638
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tyr346-->Cys mutation results in factor VIII:C assay discrepancy and a normal bleeding phenotype - is this mild haemophilia A?
    Lyall H; Hill M; Westby J; Grimley C; Dolan G
    Haemophilia; 2008 Jan; 14(1):78-80. PubMed ID: 18034822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.